Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 7/26/2025

Management of Abdominal Aortic Aneurysms

Introduction to Beta Blockers

  • Beta blockers are the preferred first-line antihypertensive agents for patients with abdominal aortic aneurysms (AAA), with propranolol being specifically recommended for its ability to reduce the force of left ventricular ejection and potentially slow aneurysm expansion, as recommended by the European Society of Cardiology 1, 2, 3

Benefits of Beta Blockers

  • Beta blockers reduce the force of left ventricular ejection (dP/dt), which weakens the arterial wall, and may slow aneurysm expansion rate, with a Class IIb recommendation and Level of Evidence B 1, 4
  • Beta blockers help achieve target blood pressure goals (systolic BP 100-120 mmHg) 1, 5

Beta Blocker Selection and Dosing

  • Propranolol is specifically mentioned in guidelines for AAA management, with a dosing of 0.05-0.15 mg/kg body weight every 4-6 hours, while esmolol is useful for initial testing in patients with potential beta blocker contraindications, with a dosing of 0.5 mg/kg over 2-5 min, followed by infusion of 0.10-0.20 mg/kg/min 1, 6
  • Metoprolol and atenolol are available for intravenous application but have longer half-times, and labetalol blocks both alpha and beta receptors and can be used in AAA patients 1

Blood Pressure Management

  • Target systolic blood pressure is 100-120 mmHg, with a more intensive systolic BP goal of <120 mmHg potentially beneficial if tolerated, as recommended by the American College of Cardiology and the European Society of Cardiology 1, 5, 2
  • For patients with diabetes or chronic renal disease, a target blood pressure of <130/80 mmHg is recommended, while for other patients, a target blood pressure of <140/90 mmHg is recommended, as suggested by the American Diabetes Association and the American Heart Association 7, 6, 5

Lipid Management

  • High-intensity statin (e.g., atorvastatin 40-80mg daily) is recommended to achieve LDL-C goal <1.4 mmol/L (55 mg/dL) and >50% reduction from baseline, with ezetimibe added if the target LDL-C goal is not achieved with statin therapy alone, as recommended by the European Society of Cardiology 2

Additional Antihypertensive Agents

  • Angiotensin Receptor Blockers (ARBs) are a reasonable adjunct to beta blocker therapy, particularly in Marfan syndrome, as suggested by the American Heart Association, while ACE Inhibitors can be used in combination with beta blockers to achieve target blood pressure 5, 6
  • Losartan has shown promise in reducing aortic dilatation in Marfan syndrome, according to the American College of Cardiology 6

Monitoring and Surveillance

  • Regular imaging surveillance is essential for AAA patients, with monitoring by ultrasound or CT scans every 6-12 months for AAAs measuring 4.0-5.4 cm, and every 2-3 years for AAAs smaller than 4.0 cm, as recommended by the European Society of Cardiology 4, 2
  • The European Society of Cardiology suggests scheduling imaging (CT or MRI) of aorta every 3-5 years based on previous findings, and using the same imaging modality with the same measurement method for consistency 2

Antiplatelet Therapy

  • Aspirin therapy (likely 81-100mg daily) is recommended for patients with a history of aortic aneurysm and cardiovascular risk factors, with no need to discontinue aspirin given its established benefit in high-risk patients, as recommended by the European Society of Cardiology 2, 8

Diabetes Management

  • Target HbA1c <7% (53 mmol/mol) is recommended, individualized based on age and comorbidities, with consideration of SGLT2 inhibitors or GLP-1 receptor agonists with proven CV benefit if diabetes is confirmed, as recommended by the American Diabetes Association and the European Society of Cardiology 7, 6, 2
  • Avoiding hypoglycemia is recommended given the patient's advanced age, as suggested by the American Diabetes Association 7

REFERENCES